Foundayo vs Wegovy: which actually works better #GLP1 #WeightLoss #Foundayo

本站添加: 2026-05-20

[00:00:00]In the landmark clinical trial called attain one, high-dose found AO was found to lead to about a 12% average weight loss from baseline over a 72-week period, and that was compared to placebo. So, a 12% loss from baseline.

[00:00:14]For some comparison, if we look at oral semaglutide and Wegovy, they sit at about 15% loss from baseline. And if we look at Zepbound, depending on the study that [snorts] you're looking at, but on average, it led to a weight loss of about 21% from baseline. Now, I will mention in that same one study, it was found that over 50% of individuals lost greater than 10% of their baseline weight, which is a good amount of weight. And over 1/3 of individuals lost greater than 15% of their baseline weight. So, it's not that the pill doesn't work. It's just that on average, it's not quite as potent and as effective as the other injectable GLP-1s we currently have on the market.